Biotechnology company Circio Holding ASA (OSE:CRNA) on Thursday reported new in vivo data showing that its AAV-circVec 4.0 platform achieved up to 50-fold higher gene expression in the eye versus conventional mRNA-based AAV following local delivery, establishing ophthalmology as a new development focus.
The data also showed a 10-fold expression advantage at a 90% lower dose, supporting the platform's potential to increase potency, reduce toxicity, and lower costs for gene therapies targeting genetic and degenerative eye diseases.
In cardiac applications, previously reported 40-fold expression gains were reproduced, with ex vivo analyses showing circVec expression in 80% of heart cells after low-dose systemic AAV delivery, validating the durability advantage of circular RNA over mRNA.
Separately, Circio raised NOK68.6m (approximately USD7m) in a 50% oversubscribed rights issue and private placements in Q1 2026 to accelerate circVec R&D, with attached warrants exercisable in June 2026 potentially extending funding into the second half of 2027.
Eli Lilly reports positive Phase 1b results for VERVE-102
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
Tenaya Therapeutics reports interim RIDGE-1 data showing reduced arrhythmia burden with TN-401
AnaCardio reports Phase 1b/2a data showing cardiac function gains with AC01
Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment
Ondine Biomedical abstracts selected for 2026 World Congress on Infectious Diseases